Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab | MicrobiomeTrials← Back to trialsNCT06136546
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-01-23Est. Completion: 2028-08-31
Enrollment target: 100 participants Locations- Massachusetts General Hospital, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Major Depressive DisorderBipolar I DisorderBipolar II DisorderMood Disorders
This 12-month, single-site prospective observational study will prospectively monitor the recurrence of mood episodes wh…
Seoul, South KoreaCompleted Oct 30, 2027
Depression - Major Depressive Disorder
The purpose of this study is to understand how the orbitofrontal cortex (OFC), a region at the front of the brain, guide…
San Francisco, United StatesEst. completion Jun 2027
Recruiting
DeliriumIntensive Care Unit DeliriumPost Intensive Care Unit SyndromePost Intensive Care Unit Syndrome Family
Almost half of critically ill patients experience delirium. Delirium is associated with impaired cognition, mortality, a…
Calgary, CanadaEst. completion Feb 1, 2030